Literature DB >> 8137296

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

C Gillett1, V Fantl, R Smith, C Fisher, J Bartek, C Dickson, D Barnes, G Peters.   

Abstract

Immunohistochemical staining with a monoclonal antibody against human cyclin D1 can be used to identify breast cancers that have an amplification of the q13 region of chromosome 11. In general, the intensity of staining is directly proportional to the degree of DNA amplification. In two unusual tumors, in which the CCND1 locus is highly amplified but staining is relatively weak, it appears that the DNA has undergone rearrangement and that the amplified/rearranged CCND1 allele may have reduced transcriptional activity. More significantly, the immunohistochemical technique identifies additional tumors in which the cyclin D1 gene is overexpressed with only marginal or undetectable increases in copy number, implying that other mechanisms can lead to deregulated expression. These results suggest that the frequency of overexpression is much higher than previously concluded from DNA-based analyses and that more than one-third of human breast cancers may contain excessive levels of cyclin D1. The technique we describe should facilitate the detection of this abnormality in a clinical setting and clarify its prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137296

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  192 in total

Review 1.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

2.  Lactation defect in mice lacking the helix-loop-helix inhibitor Id2.

Authors:  S Mori; S I Nishikawa; Y Yokota
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 3.  A specific role for cyclin D1 in mammary gland development.

Authors:  P Sicinski; R A Weinberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

4.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 5.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

6.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

7.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 8.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

9.  The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis.

Authors:  Siwanon Jirawatnotai; Samanta Sharma; Wojciech Michowski; Bhoom Suktitipat; Yan Geng; John Quackenbush; Joshua E Elias; Steven P Gygi; Yaoyu E Wang; Piotr Sicinski
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.

Authors:  Terence M Williams; Federica Sotgia; Hyangkyu Lee; Ghada Hassan; Dolores Di Vizio; Gloria Bonuccelli; Franco Capozza; Isabelle Mercier; Hallgeir Rui; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.